News

News

Higher Doses of Tofacitinib Increase Risk of Pulmonary Embolism and Death

The U.S. Food and Drug Administration (FDA) has issued a Safety Announcement after a safety clinical trial of the immunology drug tofacitinib found an...

In a Push for Open Access, University of California Cuts Ties With Major Journal...

Amid a growing global effort by academics to shift toward greater open access in research, the University of California (UC) has announced that it...

Dasatinib Granted Approval for Pediatric Indication

The FDA expanded the indication of dasatinib, a second-generation tyrosine kinase inhibitor, to include the treatment of pediatric patients (≥1 year of age) with...

Bristol-Myers Squibb to Purchase Celgene

Bristol-Myers Squibb (BMS) agreed to buy Celgene for $74 billion, making it the second-biggest purchase in the pharmaceutical and biotechnology industry and continuing a...

ELOQUENT-3: A New Elotuzumab-Based Triplet Combination in Previously Treated Myeloma

Results from the phase II ELOQUENT-3 trial demonstrate that the combination of elotuzumab plus pomalidomide and dexamethasone extended progression-free survival (PFS) compared with pomalidomide...
WIB_icon

Evaluating Midostaurin Plus Intensive Chemotherapy in Older Patients With AML

Midostaurin plus intensive chemotherapy, followed by allogeneic hematopoietic cell transplantation (alloHCT) and single-agent midostaurin maintenance therapy, was improved survival outcomes in patients with newly...

FDA Updates Guidance on Rare Disease Drug Development

The U.S. Food and Drug Administration (FDA) released a revised draft guidance for sponsors developing “orphan drugs” for the treatment or prevention of rare...

Congress Passes Bipartisan Sickle Cell Bill

The U.S. Congress recently passed the Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2018, bipartisan legislation...

Tagraxofusp-erzs Becomes First Approval for BPDCN

The U.S. Food and Drug Administration approved tagraxofusp-erzs for the treatment of adults and children (≥2 years of age) with blastic plasmacytoid dendritic cell...

FDA Approves Ravulizumab for PNH

The U.S. Food and Drug Administration (FDA) approved ravulizumab, a long-acting complement inhibitor that prevents hemolysis, for the treatment of adults with paroxysmal nocturnal...
Advertisement

Current Issue

March 2019, Volume 5, Issue 4

This issue features a look at the misconceptions about travel-associated blood clots, the treatment of young patients with myeloma, and more.